Education
About Us
Working with TipRanks
Follow Us
Mayne Pharma Group Ltd. (MAYNF)
OTHER OTC:MAYNF
MAYNF Stock Chart & Stats
$3.82
-$0.09(-2.96%)
At close: 4:00 PM EST
$3.82
-$0.09(-2.96%)
Day’s Range― - ―
52-Week Range$2.25 - $4.91
Previous CloseN/A
Volume375.00
Average Volume (3M)2.61K
Market Cap
$169.00M
Enterprise Value$344.73M
Total Cash (Recent Filing)$100.40M
Total Debt (Recent Filing)$41.27M
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Feb 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding81,245,830
10 Day Avg. Volume15
30 Day Avg. Volume2,610
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.11
Price to Sales (P/S)1.01
P/FCF Ratio79.25
Enterprise Value/Market Cap2.04
Enterprise Value/Revenue0.84
Enterprise Value/Gross Profit1.39
Enterprise Value/Ebitda8.19
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Mayne Pharma Group News
MAYNF FAQ
What was Mayne Pharma Group Ltd.’s price range in the past 12 months?
Mayne Pharma Group Ltd. lowest stock price was $2.25 and its highest was $4.91 in the past 12 months.
What is Mayne Pharma Group Ltd.’s market cap?
Mayne Pharma Group Ltd.’s market cap is $169.00M.
When is Mayne Pharma Group Ltd.’s upcoming earnings report date?
Mayne Pharma Group Ltd.’s upcoming earnings report date is Feb 19, 2026 which is in 57 days.
How were Mayne Pharma Group Ltd.’s earnings last quarter?
Mayne Pharma Group Ltd. released its earnings results on Aug 28, 2025. The company reported -$0.561 earnings per share for the quarter, missing the consensus estimate of $0.004 by -$0.565.
Is Mayne Pharma Group Ltd. overvalued?
According to Wall Street analysts Mayne Pharma Group Ltd.’s price is currently Overvalued.
Does Mayne Pharma Group Ltd. pay dividends?
Mayne Pharma Group Ltd. pays a Notavailable dividend of $0.378 which represents an annual dividend yield of N/A. See more information on Mayne Pharma Group Ltd. dividends here
What is Mayne Pharma Group Ltd.’s EPS estimate?
Mayne Pharma Group Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mayne Pharma Group Ltd. have?
Mayne Pharma Group Ltd. has 81,245,830 shares outstanding.
What happened to Mayne Pharma Group Ltd.’s price movement after its last earnings report?
Mayne Pharma Group Ltd. reported an EPS of -$0.561 in its last earnings report, missing expectations of $0.004. Following the earnings report the stock price went up 2.424%.
Which hedge fund is a major shareholder of Mayne Pharma Group Ltd.?
Currently, no hedge funds are holding shares in MAYNF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mayne Pharma Group Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
MAYNF Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth AU$401.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.78%
12-Months-Change
Fundamentals
Return on Equity
-21.13%
Trailing 12-Months
Asset Growth
-12.91%
Trailing 12-Months
Company Description
Mayne Pharma Group Ltd.
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe and Asia. The company operates through four segments: Metrics Contract Services, International, Branded Products, and Portfolio Products. It provides oral drug delivery systems; and contract pharmaceutical development, manufacturing, and analytical services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.
MAYNF Company Deck
MAYNF Earnings Call
Q4 2025
0:00 / 0:00
Technical Analysis
Cogstate Ltd
―
Immutep Ltd
―
Dimerix Limited
―
Clarity Pharmaceuticals Ltd.
―
Cyclopharm Limited
―
Ownership Overview
0.02% Insiders
2.92% Mutual Funds
<0.01% Other Institutional Investors
95.39% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---